Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

ETH47 is a first-in-class mRNA antiviral therapy with broad-spectrum potential The project will generate key preclinical and ...

Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it was awarded a ?10 million grant from EU4Health, the EU's largest ...

Organic phosphorescence materials offer advantages for bioimaging applications, but most of them are excited exclusively by ultraviolet light, which poses risks to living organisms. Here, the ...

Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems, shared key findings from its latest mRNA-LNP therapeutic research during the recent 2025 World Vaccine Congress, held in ...

Researchers describe a concentric supraparticle system that protects and delivers RNA therapeutics for gene silencing in ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

"NIIMBL members are well-positioned to advance current state-of-the-art processes and analytical technologies," said Sandeep ...

IN013, developed using Innorna’s mRNA-LNP platform, targets the root cause of WD by restoring functional ATP7B protein levels. By reducing systemic copper buildup, IN013 aims to alleviate multi-organ ...

Unlock LNP potential with enhanced clinical translatability at the 3rd Lipid Nanoparticles Development Summit Europe (24-26 September, Berlin, Germany), the leading dedicated LNP forum in Europe.